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Expansions of a hexanucleotide repeat (GGGGCC) in the noncoding region of the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Decreased expression of C9orf72 is seen in expansion carriers, suggesting that loss of function may play a role in disease. We found that two independent mouse lines lacking the C9orf72 ortholog (3110043O21Rik) in all tissues developed normally and aged without motor neuron disease. Instead, C9orf72 null mice developed progressive splenomegaly and lymphadenopathy with accumulation of engorged macrophage-like cells. C9orf72 expression was highest in myeloid cells, and the loss of C9orf72 led to lysosomal accumulation and altered immune responses in macrophages and microglia, with age-related neuroinflammation similar to C9orf72 ALS but not sporadic ALS human patient tissue. Thus, C9orf72 is required for the normal function of myeloid cells, and altered microglial function may contribute to neurodegeneration in C9orf72 expansion carriers.
A myotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders with overlapping clinical presentations, pathology, and genetic origins (1, 2) . Expansions of a GGGGCC hexanucleotide repeat in the first intron/promoter of the C9orf72 gene are the most commonly identified genetic cause of ALS/FTD (3, 4) and are found in other neurodegenerative diseases (5) . Microglial dysfunction is strongly tied to ALS/FTD pathogenesis (6), with mutations in progranulin causing FTD (7, 8) and variants in the microglial expressed genes TREM2 and TBK1 implicated in ALS (9) (10) (11) . However, no connection has been made between microglial function and C9orf 72, where focus instead has been on its role in neurons (12, 13) . Although the repeat expansion leads to decreased C9orf 72 expression in human patient tissues, most research has focused on gain-offunction toxicity as the primary mechanism in disease rather than loss of function (14) (15) (16) (17) (18) .
To investigate the function of the mouse ortholog of C9orf 72 (3110043O21Rik, referred to as C9orf 72 below), we analyzed two independent loss-of-function alleles in mice (figs. S1 and S2).
C9orf 72
+/− and C9orf 72 −/− mice showed normal weight gain and life span; had normal sensorimotor coordination, limb strength, femoral motor and sensory axon counts, and muscle electrophysiology; and showed no evidence of neurodegeneration on histology through advanced age (17 months) (figs. S1 to S3). The only histologic abnormalities in the nervous system were rare chromatolytic structures seen with hemotoxylin and eosin (H&E) staining, found in both gray and white matter of the spinal cord, that did not increase with age or show reactive gliosis ( fig. S3 ). All studies were performed using the Knockout Mouse Project line except where specified. C9orf 72 −/− mice from both lines developed visibly enlarged cervical lymph nodes and spleens ( Fig. 1, A and B) , detectable as early as 1 month after birth, that slowly enlarged with age ( Fig. 1C  and fig. S2 ). No gross or histological defects were observed in other organs at 5 months of age. Histology of lymph nodes and the white pulp of the spleen showed disruption of the normal follicular structure by enlarged debris-filled cells (Fig. 1D ) that expressed CD11b and contained ubiquitin-and p62-positive vacuoles consistent with macrophages ( Fig. 2A and fig. S4 ). Immunoblotting confirmed increased amounts of p62 and LC3 proteins, indicating an increase in components of the autophagy machinery in homozygote spleens (Fig. 2B) . Massive up-regulation of Trem2 expression was observed in C9orf 72
spleens, a cell surface receptor expressed by macrophages and monocytes, as were inflammatory cytokines, including IL-1b, IL-6, and IL-10 ( Fig.  2C ). Despite the altered follicular architecture, there were no differences in the proportions of B cells, T cells, or CD11b + myeloid cells (Fig. 2D and fig. S2J ). However, flow cytometry revealed changes in myeloid subsets, including the emergence of a CD11b +
Ly6C
Ly6G int population unique to C9orf72 −/− mice, and a decrease in F4/80 + red pulp macrophages, indicating that C9orf 72 deficiency has a selective effect on myeloid populations in the spleen (Fig. 2, E (Fig. 3F) ; however, BMDMs from both C9orf 72 −/− and to a lesser extent C9orf 72 +/− mice showed enhanced production of phagocyte oxidase-derived reactive oxygen species (ROS) after feeding with zymosan particles (Fig. 3G) , which has been reported in cells with defective fusion of phagosomes to lysosomes (20) . BMDMs from C9orf72 −/− and C9orf72 +/− mice also showed enhanced cytokine production in response to several immune stimuli, including those sensed in endosomal/lysosomal compartments such as peptidoglycan, CpG, and silica (Fig. 3, H and I) . Thus, C9orf 72 is critical for the proper function of macrophages, and the loss of C9orf 72 leads to a pro-inflammatory state that probably drives the splenic and lymph node hyperplasia. Although hemizygous mice did not have a phenotype at the tissue level, haploinsufficiency of C9orf 72 led to altered inflammatory responses in macrophages at the cellular level, which could lead to a physiological phenotype when the system is stressed.
The defects in C9orf 72
−/− BMDMs raised the possibility that other myeloid cells, including resident microglia in the brain, also require C9orf72 for normal function. Although an earlier report suggested that microglia express low levels of C9orf 72 (12), we observed that microglia showed the highest levels of C9orf 72 expression of any cell type in the brain in published data sets (21-23) (Fig. 3J ) and in quantitative reverse transcription polymerase chain reaction (qRT-PCR) of cells isolated from adult mouse brains (Fig. 3K) . Microglia from C9orf 72 −/− mice showed accumulation of LysoTracker-and Lamp1-positive structures, similar to BMDMs (Fig. 3, L and M) , whereas primary cortical neurons did not ( fig. S9 ). To probe the functional state of microglia lacking C9orf 72, we performed qRT-PCR on spinal cord microglia isolated from C9orf72 −/− mice and found increased levels of cytokines IL-6 and IL-1b, supporting the idea that the altered lysosomal function leads to a proinflammatory state (Fig. 4A ) similar to that observed in BMDMs.
Although (Fig. 4C) . To determine whether similar changes are observed in C9orf 72 ALS (C9-ALS) tissue, we analyzed a recent RNA-seq data set that includes normal controls, sporadic ALS (sALS), and C9-ALS cases (24) . Of the 19 up-regulated pathways in C9orf72 −/− mice, there was little overlap (1/19) with pathways up-regulated in sporadic ALS brain tissue (frontal cortex or cerebellum; Fig. 4D ). In contrast, the majority (10/19) of pathways up-regulated in C9orf 72 −/− mice were also up-regulated in C9-ALS human patient brains, including nearly all of the immune pathways (5/6). A direct comparison showed a significant increase in inflammatory pathways in C9-ALS versus sALS cases ( fig. S11 ). Finally, we performed immunostaining for Iba1 and Lamp1 on motor cortex and spinal cord tissue from C9-ALS (n = 3) and sALS (n = 3) cases. Although frequent reactive microglia were present in all ALS cases, microglia containing large accumulations of Lamp1-positive material were only observed in the C9-ALS cases (Fig.  4E and fig. S11 ). Thus, both transcriptome and histologic analyses of C9-ALS patient tissue are consistent with the idea that the decreased C9orf 72 expression in C9-ALS leads to altered microglial function and neuroinflammation. In summary, the loss of C9orf 72 in mice led to age-related inflammation in the spleen and nervous system, with defects in lysosomal trafficking and immune responses in macrophages and microglia. The disruption of lysosomal function in macrophages is consistent with the idea that C9orf 72 is a member of the DENN family of Rab-GEFs involved in late endosomal trafficking and autophagy (25) (26) (27) (3, (28) (29) (30) . These data raise the possibility of a dual-effect mechanism for the pathogenesis of a single gene defect: that gainof-function manifestations of C9orf 72 expansion (RNA foci and RAN dipeptides) in neurons are coupled with "primed" and dysfunctional microglia, which ultimately results in neurodegeneration (31) . Given that many ALS genes are involved in late endosomal trafficking and lysosome function (TBK1, TMEM106B, OPTN, SQSTM1, UBQLN2, VCP, CHMP2B, and PGRN) (32) and are expressed in both neurons and microglia, the concept of a dual-effect mechanism may generalize to other forms of inherited ALS. Finally, our findings raise important considerations about therapeutic knockdown of C9orf 72 in the nervous system. Although these approaches effectively target gain-of-function manifestations in neurons, they could exacerbate microglial dysfunction by further suppressing C9orf 72, unless they specifically target repeat-containing transcripts (33) mice using ASOs revealed up-regulation of immune markers in the nervous system, including Trem2 and Tyrobp (34), suggesting that innate immune function should be monitored when performing C9orf 72 knockdown strategies in humans. (red) to identify microglia and Lamp1 (green). Large accumulations of Lamp1 immunoreactivity (white arrows) were detected in activated microglia of C9-ALS but not sALS tissue.
